Client Services: 201.528.9187

An Emerging Leader In Cancer Diagnostics

Cancer Genetics, Inc. (CGI) is an emerging leader in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual.

Products and services being developed at CGI are poised to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information where patients and their physicians need it most – to diagnose, monitor and inform cancer treatment.

CGI is committed to maintaining the standard of clinical excellence through its investment in outstanding facilities and equipment. Our reference laboratory is both CLIA certified and CAP accredited, In addition we have approvals and accreditations from the states of Florida, Maryland, New York, and New Jersey.

Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, CGI’s scientific advisory board includes leading specialists in clinical cytogenetics, as well as significant thought leaders capable of driving adoption in the tri-state area. The company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, as well as strong research collaborations with major cancer centers such as Memorial Sloan-Kettering and the National Cancer Institute.

CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, we have developed a corporate culture that inspires innovation, respects knowledge and fosters leadership.

CGI’s dedicated staff takes pride in our specialized laboratory services, superior turnaround time (TAT), enhanced reporting, EMR integration, and ongoing research and development for new tests.

CGI’s full-service cancer genetic practice and path to innovation with research makes for optimal patient care management.

Subscribe to our newsletter